POM Agency Issues Emergency Use Permit for COVID-19 COVOVAX Vaccine – General Public

The Indonesian POM Agency re-issued an emergency use permit (EUA) on 17 Nov 2021 for the COVID-19 COVOVAX Vaccine.

The 11th COVID-19 vaccine that gets EUA in Indonesia is produced by the Serum Institute of India Pvt. Ltd., India (SII) and will be intended for adults aged 18 years and over.

The vaccine was administered twice with an interval of 21 days for the first and second doses, and each dose of 5 mg was injected.

It is known that the side effects (AEFI) of Covovax are mild to moderate, namely local pain, tenderness, headache, fatigue, muscle pain/myalgia, and fever.

For efficacy at the age of 18 years and over between 89.7%-90.4% for various levels of severity and ranged from 86.9%-100% for moderate-severe severity. While the efficacy in elderly vaccine recipients is known to reach 88.9% in the UK.

For information related to COVID-19, visit the official website for COVID-19 Handling and National Economic Recovery https://covid19.go.id/ and https://s.id/infovaksin

#IndonesiaBangkit #SEMUAWAJIBPAKAIMASKER

Detail:

• Tipe: Image
• Format: JPEG/PNG
• Number of Files: 2

Download Material

–

– .